A Randomized, Blinded, Parallel-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccine (LVRNA009) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated 2 Doses Inactivated SARS-CoV-2 Vaccine
Latest Information Update: 07 Feb 2023
At a glance
- Drugs LVRNA 009 (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors AIM Vaccine
Most Recent Events
- 01 Feb 2023 Planned End Date changed from 1 Jun 2024 to 1 Oct 2024.
- 01 Feb 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Oct 2023.
- 01 Feb 2023 Planned initiation date changed from 1 Dec 2022 to 1 Apr 2023.